<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00520650</url>
  </required_header>
  <id_info>
    <org_study_id>31-06-P01</org_study_id>
    <nct_id>NCT00520650</nct_id>
  </id_info>
  <brief_title>Health Evaluation of Abilify Long-term Therapy</brief_title>
  <acronym>HEALTH</acronym>
  <official_title>Health Evaluation of Abilify Long-term Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiwan Otsuka Pharm. Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taiwan Otsuka Pharm. Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a post-market surveillance, and the treatment to patients will be depended upon the
      decision based on physician's clinical judgment. The health profiles during the switching
      period, after 12 weeks short-term use, and after 52 weeks long-term use of aripiprazole will
      be recorded and evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Further study details as provided by Taiwan Otsuka Pharmaceutical Co., Ltd.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Clinical Global Impression-Severity (CGI-S) scale after 52 weeks treatment.</measure>
    <time_frame>Throughout the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in CGI-S scale at each visit during the first 39 weeks treatment.</measure>
    <time_frame>Throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total score on the Brief Psychiatric Rating Scale (BPRS) at each visit during the treatment period.</measure>
    <time_frame>Throughout the study.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total score on WHOQOL-BREF questionnaire at each visit during the treatment period.</measure>
    <time_frame>Throughout the study.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total score on PANSS (optional) questionnaire at each visit during the treatment period.</measure>
    <time_frame>throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total score on SFS (optional) questionnaire at 12 and 52 weeks treatment.</measure>
    <time_frame>Throughout the study.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Visit 2 on POM questionnaire at each visit during the 12-week switching period.</measure>
    <time_frame>Throughout the study.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-I scores after 12, 26, 39, and 52 weeks of treatment.</measure>
    <time_frame>Throughout the study.</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">245</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients between the ages of 18 to 65.

          2. Having a DSM-IV diagnosis of schizophrenia or schizoaffective disorder.

          3. Who are currently taking antipsychotic drugs and clinically intolerable or
             inadequately controlled that is based upon the clinical judgment of the investigator.

        Exclusion Criteria:

          1. Pregnant or breast feeding women or planning a pregnancy.

          2. Patient received electroconvulsive therapy within 4 weeks before the Screening Visit.

          3. A known allergy reaction to any antipsychotic medication (including but not limited to
             haloperidol, chlorpromazine, thioridazine, pimozide, risperidone, quetiapine,
             ziprasidone).

          4. Patient has clinically relevant organic, neurological, or cardiovascular diseases.

          5. Patient has a history of drug or alcohol abuse within the last 12 weeks.

          6. Acute psychosis, acute suicidal ideation, or any acute psychiatric condition that
             might require emergent intervention.

          7. Any clinical condition or significant concurrent disease judged by the investigator to
             complicate the evaluation of the study treatment.

          8. Having participated other investigational drug study and taken the investigation drug
             within one month prior to study entry.

          9. Depot neuroleptics should be discontinued at least 2 months prior to enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei-Wen Lin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tri-Service General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Changhua Christian Hospital</name>
      <address>
        <city>Changhua</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardinal Tien Hospital Hsin Chu Mercy Branch</name>
      <address>
        <city>Hsinchu</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Buddhist Tzu Chi General Hospital</name>
      <address>
        <city>Hualien</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wei Gong Memorial Hospital</name>
      <address>
        <city>Miaoli</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung Shan Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cathay General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital Yun-Lin Branch</name>
      <address>
        <city>Yun-Lin</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2007</study_first_submitted>
  <study_first_submitted_qc>August 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2007</study_first_posted>
  <last_update_submitted>December 15, 2009</last_update_submitted>
  <last_update_submitted_qc>December 15, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>Edward C.Y. Peng</name_title>
    <organization>Taiwan Otsuka Pharm. Co., Ltd</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

